AC
AGRX

Aisling Capital’s Agile Therapeutics AGRX Stock Holding History

Aisling Capital’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-652
Closed -$3.35M – 10
2018
Q1 		$3.35M Hold
652
– – 0.6% 7
2017
Q4 		$3.51M Sell
652
-250
-28% -$2.33M 0.69% 9
2017
Q3 		$8.05M Hold
902
– – 1.32% 9
2017
Q2 		$6.77M Hold
902
– – 1.16% 11
2017
Q1 		$5.78M Hold
902
– – 1.05% 13
2016
Q4 		$10.3M Sell
902
-236
-21% -$3.31M 2.39% 11
2016
Q3 		$15.9M Sell
1,138
-154
-12% -$2.2M 3.27% 11
2016
Q2 		$19.7M Sell
1,292
-200
-13% -$2.74M 4.64% 9
2016
Q1 		$18.5M Hold
1,492
– – 3.71% 12
2015
Q4 		$29.1M Hold
1,492
– – 5.02% 7
2015
Q3 		$20.1M Hold
1,492
– – 3.54% 11
2015
Q2 		$25.6M Hold
1,492
– – 3.82% 10
2015
Q1 		$27.7M Buy
1,492
+406
+37% +$7.12M 3.62% 10
2014
Q4 		$13.3M Hold
1,086
– – 2.02% 15
2014
Q3 		$15.8M Hold
1,086
– – 3.07% 12
2014
Q2 		$18.9M Buy
+1,086
New +$15.7M 5.47% 8

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aisling Capital's AGRX Position: Q2 2018 in Review

Aisling Capital sold out of Agile Therapeutics (AGRX) in Q2 2018, closing a stake of 652 shares — an estimated $3.35M sold.

Aisling Capital first reported a position in AGRX in Q2 2014 and held it in 16 quarters. The position peaked at $29.1M in Q4 2015. 38 funds tracked by Wall St. Rank hold AGRX as of Q2 2018.

  • Aisling Capital reported no remaining Agile Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Aisling Capital sold 652 Agile Therapeutics shares in Q2 2018, an estimated $3.35M.
  • Aisling Capital first reported a position in Agile Therapeutics in Q2 2014 and held it in 16 quarters.
  • Aisling Capital's Agile Therapeutics position peaked at $29.1M in Q4 2015.
  • 38 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2018.

Based on Aisling Capital's 13F filing for Q2 2018, filed 13 Aug 2018.